Open Access<p>JuBei Oral Liquid Induces Mitochondria-Mediated Apoptosis in NSCLC Cells</p>
Author(s) -
Zhenzhen Pan,
Qiufang Chen,
Xiaodong Zheng,
Kai Wang,
Yalei Duan,
Kang Xiao,
Zhirong Jia,
Xiaowen Ding
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s254464
Subject(s) - gefitinib , apoptosis , viability assay , protein kinase b , pi3k/akt/mtor pathway , mitochondrion , cell growth , cancer research , programmed cell death , mtt assay , microbiology and biotechnology , chemistry , biology , epidermal growth factor receptor , receptor , biochemistry
Although gefitinib brings about tremendous advances in the treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, most of patients become incurable due to drug resistance. JuBei oral liquid (JB) has been widely used to treat pneumonia in clinic. Components of JB were reported to induce apoptosis in NSCLC, which indicated that JB could be a potential antitumor agent for NSCLC patients. In this study, we investigated the effect of JB on gefitinib-sensitive PC-9 and gefitinib-resistant PC-9/GR, H1975 cells as well as its underlying molecular mechanisms.